Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epirubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 9/20 | 1.00 |
| ▸ | THRB | P10828 | 8/20 | 1.00 |
| ▸ | BLM | P54132 | 8/20 | 1.00 |
| ▸ | RECQL | P46063 | 7/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | STAT6 | P42226 | 4/20 | 1.00 |
| ▸ | HTT | P42858 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epirubicin SCHEMBL12349863 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL1501770 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL21184881 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL14227487 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL24421866 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL14562311 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL23365786 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL22403027 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL21914951 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL22291815 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 148305 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4747388-A1 | RECOMBINANT BACTERIAL CELL CAPABLE OF EXPRESSING A HETEROLOGOUS EXTRACELLULAR MATRIX (ECM) DEGRADING POLYPEPTIDE USING A TUMOUR-INDUCIBLE PROMOTER | NEOBE THERAPEUTICS LTD (GB) | 2026-05-27 | — | — | EP | claimed |
| CN-116794308-B | Application of beta-1, 4-galactosyltransferase 1 and inhibitor thereof in preparation of medicines for treating acute and chronic liver diseases | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-122075728-A | PH/GSH space-time cascade response type anti-tumor nano-drug and preparation method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122074446-A | Construction method of radiorecall dermatitis rat model | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075672-A | Application of hD1R protein in preparation of medicine for treating AML | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075411-A | Tripterine liposome, its combined medicine and its application in preventing and treating tumor | — | 2026-05-26 | — | — | CN | claimed |
| CN-117624275-B | Liver-targeting sugar ligand molecule modified by double-antenna GalNAc and drug carrying system thereof | JIAYING UNIVERSITY (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| US-4950738-A | ANTICARCINOGENS | CYTOGEN CORPORATION (US) | 1990-08-21 | — | — | US | claimed |
| EP-0361894-A2 | Loading and controlled release of amphiphatic molecules to and from liposomes | YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1990-04-04 | — | — | EP | claimed |
| EP-0328147-A2 | Anthracycline immunoconjugates having a novel linker and methods for their production | Bristol-Myers Squibb Company (US) | 1989-08-16 | — | — | EP | claimed |
| WO-1989000846-A1 | METHOD FOR SIZE SEPARATION OF PARTICLES | THE LIPOSOME COMPANY, INC. (US) | 1989-02-09 | — | — | WO | claimed |
| WO-1988009823-A1 | AMINE DERIVATIVES OF ANTHRACYCLINE ANTIBIOTICS AND ANTIBODY CONJUGATES THEREOF | CYTOGEN CORPORATION (US) | 1988-12-15 | — | — | WO | claimed |
| EP-0294294-A2 | Amine derivatives of anthracycline antibiotics | CYTOGEN CORPORATION (US) | 1988-12-07 | — | — | EP | claimed |
| EP-0290296-A2 | Liposomal formulations with a high antineoplastic agent/lipid ratio | THE LIPOSOME COMPANY, INC. (US) | 1988-11-09 | — | — | EP | claimed |
| WO-1988006442-A1 | HIGH DRUG:LIPID FORMULATIONS OF LIPOSOMAL-ANTINEOPLASTIC AGENTS | THE LIPOSOME COMPANY, INC. (US) | 1988-09-07 | — | — | WO | claimed |
| EP-0280167-A2 | Use of lipophile anthracyclines for the secondary treatment of anthracycline-resistant tumors, composition containing a lipophile anthracycline and preparation thereof | BEHRINGWERKE Aktiengesellschaft (DE) | 1988-08-31 | — | — | EP | claimed |
| EP-0253654-A2 | Continuous process for transforming 4'-keto-N-trifluoroacetyldaunorubicin into 4'-epi-N-trifluoroacetyl-daunorubicin, an intermediate for preparing an anti-tumour compound | FARMITALIA CARLO ERBA S.r.l. (IT) | 1988-01-20 | — | — | EP | claimed |